Dr. Ashok Srivastava is Chief Executive Officer and Chief Medical Officer of Cure Pharmaceuticals, and ClinFomatrix Oncology CRO, He was founder, Chief Executive Officer and Chief Medical Officer of Care Beyond - A Radiation Therapy Cancer Center, New Jersey. USA. He has more than 15 years of experience in drug development, medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase 1 – 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in USA, EU and Japan. He is leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials. He contributed to 21-INDs and 7-NDAs of Cancer Drugs, acquisition /merger of company and drug for more than $900 million. He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide at various executive leadership positions; Walter Reed Army Institute of Research and Medical Center, Daiichi Pharmaceuticals, Sumitomo Pharmaceuticals, Pharmacia, Pfizer, Eisai Oncology, Spectrum Pharmaceuticals and Taiho Oncology. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive for metastatic breast cancer patients and Latuda (Lurasidone) for schizophrenia. He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer and Taiho Oncology in USA, EU and India. Dr. Srivastava is member of numerous prestigious organizations; America’s Top Oncologist of the years 2017, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development. Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, immuno-oncology and built global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in London, UK, India and Washington, DC, USA in 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approximately 3 – 3.5 billion $ in global sales. He serves as board of directors for oncology pharma companies in USA.

Global complex mega cancer drug trial & generic drugs drug development and medical affairs R&D & medical affairs; Phase I-IV and Life Cycle Management Chemotherapy, Immuno-oncology, Supportive Care Alliance Management/Joint Steering Committee Building High Performing Teams

He is the Senior Director and head of Global Pharmacovigilance at Cipla. He is a Senior Manager, Strategic Planning and Pharmacovigilance Operations, Supplier performance Management at Amgen. A Medical Doctor and a certified Project Management Professional PMP.I have done my M.Phil. in Biostatistics and I am involved in Drug Safety and risk and Managemen. He have done Executive Program in Strategic Management from IIM Rohtak. He have 16 years of total experience which includes 6 years of direct patient care experience as a doctor in various capacities including Medical / Cardiac / Post-surgical ICU and 11 years of experience in pharmaceutical industry in various functions like Pharmacovigilance, BA/BE and Medical Affairs/Medical Information. My experience as a physician is well utilized in safety and risk management activities. He have hands-on experience in managing and leading a pharmacovigilance department in a pharmaceutical company and the activities therein viz. initiating and designing SDEA's, SLA's, all aspects of ICSR case processing, Medical review of ICSRs, Medical and Safety review of aggregate reports, Benefit-Risk analysis reports, Signal detection and interactions with regulatory authorities. He have worked with pharmaceutical companies and pharmacovigilance service providers enabling me to view issues from both sides of the table.

Pharmacovigilance & Drug Safety Biostatistics Clinical Research, BA/BE Internal Medicine

Md. Gayoor khan has Perusing his Bachelor of Pharmacy at the University TRUBA INSTITUTE OF PHARMACY Bhopal Madhya Pradesh. He is the founder & National President of NFPS, a Globally Working organization. He has published more than 17 papers in reputed journals and has been serving as a liaison officer USM Malaysia, CEC Member IHPA- SF, Business Associate kp Lab's, President GOMHA Student wing, Project Manager in health care department at Clyto access Pvt,ltd , Training Associate in clinitech.

Pharmacovigilance,Pharmacy,Clinical Trials

He is completed his Doctor of Medicine in 1997 in Thammasat University and he studied family medicine in The Royal colleges of Family Physicians of Thailand. In 200, he is a medical lecturer of Basic Pharmacology and clinical Pharmacology and Doctor of Medicine in clinical practitioner for chulalongkom university staffs for the department of pharmacology, faculty of medicine, Chulalongkorn university. In 2013, He worked as Product Physician (Medical Advisor) in Pfizer (Thailand) Ltd. He served as Researcher and program Manager in department of Thai traditional and alternative medicine, ministry of public health. 2014 – 2018 Physician in Vichaiyut hospital department of internal medicine. He Honored and Awarded for an outstanding Biological sciences study, The Sciences Society of Thailand under the Patronage of H.M. the King.

Systematic program and technology implementation for the elderly physical and mental health: Global health development of the quality of living by the innovative technology of health care.Ubiquitous Healthcare (focusing on health data management and electronic medical information for the aging)

I have diverse leadership experience as a health services professional with significant accomplishments in all aspects of pharmacovigilance, clinical development, medical affairs, regulatory affairs, primary health care, project management & international health programs. I have vast experience of working in diverse therapeutic areas including rare diseases, novel preventive & therapeutic vaccines, monoclonal antibodies, cardiovascular, oncology, neurology, nosocomial diseases, generic and OTC medicines. I am currently working as Disease Area Cluster Lead for Biosimilars & Drug Delivery Devices at Pfizer. Currently Pfizer has the largest biosimilars portfolio in the industry that includes projects on Inflammation, Oncology, Hematology, ophthalmology etc. My past experience includes working as Associate vice president PV and Therapeutic Area Head (Rare Diseases) for Sanofi Genzyme, working as Senior Director & Director for vaccines PV at Sanofi Pasteur, working as Medical Consultant for Apotex Inc Canada. Prior to joining industry I had worked as Joint Executive Director for Pakistan Institute of Medical Sciences (PIMS), Registrar of the Post graduate medical institute PIMS and as Deputy Director General, Ministry of Health Pakistan. I have also worked on various primary healthcare, public health, health planning & development programs as well World food, UNICEF, WHO & JICA assisted programs on drug safety, emergency preparedness, and primary healthcare.

Pharmacovigilance, Drug safety

Swamy K B has been awarded with PhD by Andhra University, his Master’s Degree MS (in Clinical Anatomy) from Andhra Medical College, D M C h (Maternal & Child Health) from IGNOU, New Delhi, his Medical Degree (MBBS) in 1976, from SV University, India. He has expertise in multi medical disciplines, Human Genetics, Reproductive Health & Developmental Anatomy and in Herbal Medicine. He has been the genetic counsellor for many Medical institutions. He possess prestigious grants FRGS,URGS from Malaysia, he has conducted researches on Herbal Medicine and Diabetes, “Brain size and Intelligence Quotient (IQ)”, He has been the former founder Anatomist, Professor and Head for many Medical Schools in India as well as in Malaysia. He is an International Editorial Board Member for many reputed journals like Anatomical Society of India (ASI). Recently he has been unanimously elected as an Executive Board Member for ASI and an Organizing Committee Member for the upcoming 8th World Congress on Toxicology at Dubai, UAE “9th Euro-Global Summit to be held at Paris and 11th International Congress on Toxicology and Risk Management to be held at October 10-12, 2017 in London, UK.

Human Genetics, Reproductive Health & Developmental Anatomy and in Herbal Medicine.

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Dr. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. His group has identified numerous small molecules from natural sources that can suppress various pro-tumorigenic signaling cascades involved in cancer initiation and promotion. The findings of his research work have so far resulted in more than one fifty scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves as an Academic Editor for prestigious PLOS One journal and on the editorial board member of several journals including Scientific Reports and Frontiers in Pharmacology

Pharmacology, Pharmacovigilance,Drug Safety

He is a chair of St. Anne's University Hospital

Advance knowledge, improve clinical care and promote advocacy to power better quality of life of patients with dementia

Shibo Jiang received postdoctoral training at Rockefeller University (1987-1990) and worked as Member and Lab Head at the New York Blood Center (1990-2010), and as a professor (Thousands-talent scholar) at Fudan University (2010-). He has focused on development of antiviral therapeutics and vaccines. He discovered the first highly potent anti-HIV peptide and his patent was licensed to Trimeries Pharmaceutical for developing the first US FDA-approved peptide HIV entry inhibitor - Fuzeon (enfuvirtide or T20). He developed the first anti-HPV therapeutic - JB01 protein. He has published 360 SCI papers in high profile journals (e.g., Nature, Nature Medicine, Nature Communication, Nature Review Microbiology, Lancet, Cell, PNAS etc) with total impact factors of 1,686 and >10,000 citations. He has obtained 18 US and 5 Chinese patents, 8 US NIH grants (>20 millions USD) and 8 Chinese grants (>20 millions RMB), and given more than 180 oral presentations in more than 30 countries

Drug Safety, Pharmacovigilance,HPV

Dr. Yusuf TUTAR is the Head of Biochemistry Division and the Head of Basic Sciences Department at Faculty of Pharmacy, Cumhuriyet University, Sivas Turkey. Dr. Tutar is also the Head of Biomedical Engineering Program at the same university. He obtained his M.Sc. and Ph.D. at Oregon State University and Texas Tech University respectively. He pursued his postdoctoral study at National Institutes of Health (NIH/NIDDK), USA

His research focuses on Biochemistry, Biophysics, Genetics, and Molecular Biology with specialization in the fields of protein structure-function, protein folding, prion, microrna, pseudogenes, molecular cancer, proteomics, genomics, protein expression and characterization by spectroscopic and calorimetric methods.

Dr. Nagwa Ali Sabri is a Professor of Clinical Pharmacy and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Egypt. She has a Diploma in Medical Informatics from SIRA Institute, USA., IRCA Certified Lead Auditor ISO 9001:2015 and Certified Pharmacovigilance Specialist (Qualified Person for Pharmacovigilance (QPPV). She is a Principal Investigator and member of institutional review board of Drug Research Centre (Bioequivalence Centre, Cairo-Egypt). Member in Biocides Technical Committee of Ministry of Health. Dr. Nagwa’s areas of interest include; teaching, supervising different activities of under and post-graduate students, investment of clinical pharmacy activities in community pharmacies and hospitals, undergoing Bioequivalence and Bio-waiver studies according to international guidelines and Pharmacovigilance. She has more than 25 years of academic experience, and more than 19 years of experience in bioequivalence and advanced pharmaceutical research, principal investigator in about 300 Bioequivalence studies, Bio-waiver studies, expert reports and others. She owns a significant experience in establishment of quality assurance system and advanced training schedule in Bioequivalence and Pharmacovigilance field. She has more than 45 published researches and more than 30 national and international awards and prizes.

Clinical Pharmacy Practice and Pharmacotherapy. -Bioequivalence, Pharmacokinetics and Clinical Pharmacokinetics. -Pharmacovigilance. - Clinical Trials. -Pharmaceutics, drug formulation, in vitro testing (dissolution, disintegration, weight variation,…etc). -Analytical Method development and its application (HPLC and LC/MS/MS). - Quality Assurance Systems, Certification and Accreditaion.

Samar N. El-Beshbishi has completed here PhD-research and postdoctoral studies from University of Texas Medical Branch, Galveston, Texas-USA. She is professor of Medical Parasitology, Faculty of Medicine, Mansoura University, Egypt. She has her expertise in schistosomal therapeutic and immunological studies. She has published more than 30 papers in reputed journals and has been serving as an editorial board member and reviewer of repute.

Pharmacovigilance, Parasitology

Presently working as a Principal Scientist in the Department of Pulmonary Medicine and Sleep Disorders, AIIMS, New Delhi. Diligent & competent professional with a trailblazing 12 years of committed clinical health research experience. Post Doctoral Fellowship in Clinical Health (Genetics of obesity, fatty liver and sleep medicine), from Department of PMSD, AIIMS, New Delhi, India PhD in clinical health (Biotechnology) from AIIMS, Institute of Genomics & Integrative Biology (IGIB) and Jamia Hamdard University, New Delhi, India. Academically proficient with Master in Business Administration (MBA) in Human Resource (HR) from Guru Jameshawar University Haryana and Master in Science (M.Sc) in Biomedical Science and Post Graduate Diploma In Biomedical Technology from Garhwal University, Uttarakhand.

Genetics of obesity, diabetes, fatty liver, obstructive sleep apnea, cardiovascular disease and vitamin D deficiency

Presently working as an Assistant Professor of Clinical Pharmacy in the Department of Clinical Pharmacy, Faculty of Pharmacy, Guilan University of Medical Sciences. Graduated with Pharm.D degree from School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran in 2011. After graduation, she began the academic study program for degree of specialty in pharmacotherapy in Tehran University of Medical Sciences, Tehran, Iran and obtained her certificate in clinical pharmacy specialty.

Pharmacotherapy, Pharmacovigilance, Drug utilization evaluation, Clinical trials, Drug-induced Nephrotoxicity